RxDoctor Payments DataLook up a doctor →

James Cain, MD

Family Medicine · Lampasas, TXNPI 1467434464

Payments from drug & device makers

$2,889,514in general payments, 2019–2025

Across 1,481 payments — averaging $1951.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1M
  • Pfizer$643K
  • Sanofi Pasteur Inc.$296K
  • Merck$264K
  • Supernus Pharmaceuticals, Inc.$180K
  • AstraZeneca$130K
  • plus $337K from 35 others
$71,047in research payments, 2019–2025

Across 23 payments — averaging $3088.98 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Applied Therapeutics, Inc.$71K

What the payments were for

  • Consulting fees$4,55054%
  • Travel & lodging$80610%
  • Food & beverage$3,01536%
  • Education$190%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,889,514 in reported general payments places this provider in the 95th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$14,203
Medicare patients
353
Services billed
712

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide111$148,950
MounjaroTirzepatide71$76,426
EliquisApixaban61$43,434
JanuviaSitagliptin Phosphate52$42,123
TrulicityDulaglutide29$36,123
JardianceEmpagliflozin20$25,890
XareltoRivaroxaban25$21,511
MyrbetriqMirabegron22$16,153
Lantus SolostarInsulin Glargine,hum.Rec.Anlog28$6,883
Atorvastatin Calcium482$6,134
LantusInsulin Glargine,hum.Rec.Anlog15$4,134
Levemir FlexpenInsulin Detemir17$3,681
Omeprazole233$3,643
Tamsulosin Hcl140$3,434
Levothyroxine Sodium315$3,312

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$484$148,950111 claims
Lilly USA, LLCMounjaro, Trulicity$116$112,550100 claims
PfizerEliquis$643,301$43,43461 claims
MerckJanuvia$264,257$42,12352 claims
Boehringer IngelheimJardiance$76$25,89020 claims
Johnson & JohnsonXarelto$11$21,51125 claims
Sanofi-aventis U.S. LLCLantus$28$4,13415 claims
AbbVieSynthroid$1,037,556$1,88818 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Lampasas

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →